Back to homepage

Haematology and Oncology

Evaluating cost benefits of combination therapies for advanced melanoma

Authors: Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.

More

Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data

Authors: Paul Harper, Emmanuel J Favaloro, Julie Curtin, Chris Barnes, Scott Dunkley

Human plasma-derived factor VIII/von Willebrand factor complex concentrates are used to control bleeding in patients with von Willebrand disease (VWD) or haemophilia A (HA). This article provides an extensive overview of the molecular properties, in addition to pharmacokinetic, efficacy and safety data, and case studies of clinical experience of one such concentrate, Biostate.

More

Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies

Authors: Sarah L Scarpace

Lung cancer is the third most commonly diagnosed cancer and the leading cause of cancer-related death in the United States. This paper provides an overview of drug therapy options for squamous cell NSCLC with a focus on the evidence and clinical application of the anti-PD1 therapies. A comparison of the dosing, administration, indications, and differences in the measurement of PD-L1 expression in the clinical trials of nivolumab and pembrolizumab is also provided.

More

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

Authors: Marco Turini, Vittoria Piovesana, Pierfrancesco Ruffo, Claudio Ripellino, Nazarena Cataldo

Inadequately treated, chemotherapy-induced nausea and vomiting (CINV) can lead to increased resource utilization and severely impair patients’ daily functioning and quality of life. The authors investigated the management of CINV episodes in three European health-care environments and estimate the direct costs associated with severe CINV episodes.

More

Diagnosis and management of lentigo maligna: a review

Authors: Julia M Kasprzak, Yaohul G Xu

In lentigo maligna, the ill-defined nature and potentially large size of lesions can pose significant diagnostic and treatment challenges. The goal of therapy is to cure the lesions in order to prevent development of invasive disease. In this article the authors describe techniques for surgical excision, which is currently the treatment of choice to achieve clear histological margins, and review the evidence for nonsurgical treatment modalities.

More